Why the study?
While SGLT2 inhibitors provide cardiovascular and renal benefits in heart failure, their benefit in heart failure due to cancer therapy-related cardiac dysfunction remains to be established.
Do SGLT2 inhibitors reduce heart failure events and mortality in patients undergoing chemotherapy at risk of cancer therapy-related cardiac dysfunction?
Population
27,165 patients undergoing chemotherapy at risk of developing CTRCD
Comparison
SGLT2 inhibitors vs control
Design
Systematic review and meta-analysis of 1 RCT and 11 observational cohorts
Key result
SGLT2 inhibitors reduced new heart failure events by 74% (RR 0.26), HF hospitalizations by 54% (RR 0.46), and all-cause mortality by 53% (RR 0.47) in chemotherapy patients.
Authors
Loading...
May warrant SGLT2 inhibitor use in chemotherapy patients; extends HF and mortality benefits to a new high-risk population.
Do SGLT2 inhibitors reduce heart failure events and mortality in patients undergoing chemotherapy at risk of cancer therapy-related cardiac dysfunction?
SGLT2 inhibitors may offer significant cardioprotective benefits, including reduced risks of new-onset heart failure and all-cause mortality, in patients undergoing chemotherapy.
Huntermann et al. (2025) studied this question. SGLT2 inhibitors reduced new heart failure events by 74% (RR 0.26), HF hospitalizations by 54% (RR 0.46), and all-cause mortality by 53% (RR 0.47) in chemotherapy patients.